PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.82%
Similar R&D growth to TRAW's 52.21%. Walter Schloss would investigate industry innovation requirements.
-14.04%
G&A reduction while TRAW shows 90.15% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.04%
Operating expenses growth less than half of TRAW's 61.20%. David Dodd would verify sustainability.
9.04%
Total costs growth less than half of TRAW's 61.20%. David Dodd would verify sustainability.
104.89%
Interest expense growth while TRAW reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
-9.04%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-9.04%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
114.37%
Other expenses growth above 1.5x TRAW's 36.36%. Michael Burry would check for concerning trends.
48.96%
Pre-tax income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
135.99%
Tax expense change of 135.99% while TRAW maintains burden. Bruce Berkowitz would investigate strategy.
48.96%
Net income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
53.59%
EPS growth while TRAW declines. John Neff would investigate advantages.
51.99%
Diluted EPS growth while TRAW declines. John Neff would investigate advantages.
10.21%
Share count increase while TRAW reduces shares. John Neff would investigate differences.
6.42%
Diluted share increase while TRAW reduces shares. John Neff would investigate differences.